Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Cheyne Capital Management (UK) LLP

Q4 2022 · 13F-HR

Cheyne Capital Management (UK) LLPholdings as filed

Filed 2023-02-10 · accession 0001567619-23-002236

$57.2M
Reported value
59
Positions
2022-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
00507V109AIYACTIVISION BLIZZARD INC$7.9M13.8%103,136CommonSOLE
165167735EXECHESAPEAKE ENERGY CORP.$3.7M6.51%39,506CommonSOLE
067901108ABXBARRICK GOLD CORP.$3.4M6.00%200,000CommonSOLE
750491102RDNTRADNET INC$2.1M3.67%111,427CommonSOLE
30744W107FTCHQFARFETCH LTD$2.0M3.44%416,500CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$1.7M2.93%42,500CommonSOLE
867224107SUSUNCOR ENERGY INC NEW$1.5M2.57%46,300CommonSOLE
674599105OXYOCCIDENTAL PETE CORP$1.5M2.56%23,300CommonSOLE
75382E109RAPT THERAPEUTICS INC$1.4M2.49%71,828CommonSOLE
00768Y453MSOSADVISORSHARES TR$1.4M2.47%202,000CommonSOLE
02083G100NVLSEURALPINE IMMUNE SCIENCES INC$1.3M2.34%181,886CommonSOLE
44332N106HTHTH WORLD GROUP LTD$1.3M2.30%31,000CommonSOLE
92243G108PCVXVAXCYTE INC$1.3M2.25%26,849CommonSOLE
729139105PLRXPLIANT THERAPEUTICS INC$1.3M2.23%66,144CommonSOLE
G65431127NENOBLE CORP PLC$1.2M2.12%32,100CommonSOLE
090043100BILLBILL COM HLDGS INC$1.2M2.08%10,940CommonSOLE
878742204TECKTECK RESOURCES LTD$1.1M1.86%28,100CommonSOLE
81181C104SEAGEN INC$1.0M1.80%8,025CommonSOLE
15135U109CVECENOVUS ENERGY INC$1.0M1.80%53,000CommonSOLE
730541109POINT BIOPHARMA GLOBAL INC$926,4861.62%127,090CommonSOLE
46583P102IVERIC BIO INC$883,1631.54%41,250CommonSOLE
01609W102BABAALIBABA GROUP HLDG LTD$863,2821.51%9,800CommonSOLE
008474108AEMAGNICO EAGLE MINES LTD$852,6361.49%16,400CommonSOLE
17240Y109CINCOR PHARMA INC$830,2761.45%67,557CommonSOLE
13057Q305CRCCALIFORNIA RES CORP$817,3351.43%18,785CommonSOLE
00461U105ACRSACLARIS THERAPEUTICS INC$802,6831.40%50,964CommonSOLE
427746102HRTXHERON THERAPEUTICS INC$795,0201.39%318,008CommonSOLE
90400D108RAREULTRAGENYX PHARMACEUTICAL IN$792,9381.39%17,115CommonSOLE
68404V100OPTINOSE INC$730,2641.28%394,737CommonSOLE
90353T100UBERUBER TECHNOLOGIES INC$722,1161.26%29,200CommonSOLE
92332V107VTYXUSDVENTYX BIOSCIENCES INC$656,9481.15%20,035CommonSOLE
92686J106VKTXVIKING THERAPEUTICS INC$608,6781.06%64,753CommonSOLE
23954D109DAWNGBXDAY ONE BIOPHARMACEUTICALS I$585,8391.02%27,223CommonSOLE
13321L108CCJCAMECO CORP$582,6191.02%25,700CommonSOLE
69366J200PTCTPTC THERAPEUTICS INC$576,5961.01%15,106CommonSOLE
008064107AEROVATE THERAPEUTICS INC$554,5610.97%18,927CommonSOLE
674599105OXYOCCIDENTAL PETE CORP$536,0500.94%302CALLSOLE
697900108PAASPAN AMERN SILVER CORP$503,2720.88%30,800CommonSOLE
89422G107TVTXTRAVERE THERAPEUTICS INC$499,4630.87%23,750CommonSOLE
23257D103CBAYUSDCYMABAY THERAPEUTICS INC$485,9190.85%77,499CommonSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$472,9670.83%3,650CommonSOLE
26884L109EQTEQT CORP$412,7260.72%12,200CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$356,8600.62%52,790CommonSOLE
03237H101AMLXAMYLYX PHARMACEUTICALS INC$350,9880.61%9,499CommonSOLE
61559X104MLTXMOONLAKE IMMUNOTHERAPEUTICS$337,3550.59%32,129CommonSOLE
45845P108INTERCEPT PHARMACEUTICALS IN$327,1000.57%26,443CommonSOLE
00509G209ABOSACUMEN PHARMACEUTICALS INC$301,4770.53%55,829CommonSOLE
60468T105MRTXEURMIRATI THERAPEUTICS INC$301,3120.53%6,650CommonSOLE
92539P101VERVE THERAPEUTICS INC$290,2500.51%15,000CommonSOLE
01345P106BDQMALBIREO PHARMA INC$288,7960.50%13,364CommonSOLE
517125100LRMRLARIMAR THERAPEUTICS INC$262,9980.46%63,680CommonSOLE
08579X101BRYBERRY CORP$248,0000.43%31,000CommonSOLE
01675A109BIRDGBPALLBIRDS INC$242,0000.42%100,000CommonSOLE
74019P108PRECISION BIOSCIENCES INC$226,1770.40%190,065CommonSOLE
38406L103GRACELL BIOTECHNOLOGIES INC$225,6760.39%98,120CommonSOLE
75281A109RRCRANGE RES CORP$225,1800.39%9,000CommonSOLE
845467109SWN1EURSOUTHWESTERN ENERGY CO$216,4500.38%37,000CommonSOLE
37148K100GBIOGBXGENERATION BIO CO$200,9250.35%51,126CommonSOLE
55910K108MAGENTA THERAPEUTICS INC$18,6320.03%47,170CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.